Intravitreal Ranibizumabe
ApprovedSmall molecule
Intravitreal Ranibizumabe is one of 84 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Approved.
3
Indications
4
Total Trials
0
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
73 competitors in Retinitis Pigmentosa
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPhase 3
Aquasol a
BBandim Health Project
Phase 3
Minocin
TTriax
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Depakote
AbbViePhase 2
Intravitreal Ranibizumabe
UUniversity of Sao Paulo
Approved
Eylea
RegeneronPhase 2
Alphagan
AbbViePhase 2
Lutein
NNational Eye Institute (NEI)
Phase 3
Levodopa-Carbidopa
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Retinitis Pigmentosa2 trials
Proliferative Diabetic Retinopathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intravitreal Ranibizumabe. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Sao Paulo